Scarica l'app Stockscreener
2.63
6.48%
0.16
Precedente Chiudi:
$2.47
Aprire:
$2.51
Volume 24 ore:
50,926
Relative Volume:
0.20
Capitalizzazione di mercato:
$54.94M
Reddito:
-
Utile/perdita netta:
$-94.11M
Rapporto P/E:
-0.4376
EPS:
-6.01
Flusso di cassa netto:
$-86.06M
1 W Prestazione:
+4.37%
1M Prestazione:
+3.54%
6M Prestazione:
-38.69%
1 anno Prestazione:
-61.09%
Intervallo 1D:
$2.50
$2.66
Intervallo di 1 settimana:
$2.20
$2.66
Portata 52W:
$1.78
$8.56
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Nome
Adverum Biotechnologies Inc
Settore
Industria
Telefono
(650) 649-1004
Indirizzo
100 CARDINAL WAY, REDWOOD CITY, CA
Confronta ADVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
2.63 | 46.80M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.88 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.26 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.03 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.45 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
302.05 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Aggiornamento | Truist | Hold → Buy |
| 2021-07-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Downgrade | Truist | Buy → Hold |
| 2020-12-16 | Iniziato | UBS | Neutral |
| 2020-11-12 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-05 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-28 | Iniziato | Goldman | Buy |
| 2020-03-16 | Iniziato | SVB Leerink | Outperform |
| 2020-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-09-13 | Reiterato | Chardan Capital Markets | Neutral |
| 2019-06-14 | Ripresa | Raymond James | Mkt Perform |
| 2018-11-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Downgrade | SunTrust | Buy → Hold |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Iniziato | SunTrust | Buy |
| 2018-02-15 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie
Published on: 2025-08-13 08:22:03 - Newser
Adverum Biotechnologies: Q2 Earnings Snapshot - New Haven Register
Full technical analysis of Adverum Biotechnologies Inc. stockJuly 2025 Movers & Real-Time Volume Analysis Alerts - Newser
How high can Adverum Biotechnologies Inc. stock price go in 20252025 Volatility Report & Long-Term Growth Stock Strategies - Newser
Adverum Biotechnologies Faces Financial Hurdles Amid Gene Therapy Development - AInvest
Adverum Biotechnologies Faces Financial Challenges Amid Gene Therapy Development - TipRanks
Adverum Biotechnologies shares fall 8.91% after-hours after reporting a larger-than-expected Q2 loss. - AInvest
Adverum Biotechnologies shares rise 4.86% after-hours despite reporting a $49.2 million loss in Q2. - AInvest
Adverum Biotechnologies Q2: ARTEMIS Phase 3 enrollment exceeds expectations. - AInvest
Adverum Biotechnologies Q2 GAAP EPS Misses Expectations, Cash Holdings Down to $44.4M - AInvest
Adverum Biotechnologies Reports Q2 2025 Financial Results, Exceeds ARTEMIS Enrollment Expectations, Announces $10M Private Placement with Frazier Life Sciences. - AInvest
Adverum Biotechnologies, Inc. SEC 10-Q Report - TradingView
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - GlobeNewswire
Adverum Biotechnologies Q2: ARTEMIS Phase 3 Enrollment Exceeds Expectations, $10mln Private Placement - AInvest
Adverum's One-and-Done Eye Treatment Attracts Record Trial Enrollment as 50% of Specialists Back Gene Therapy - Stock Titan
Technical signs of recovery in Adverum Biotechnologies Inc.3-Year Equity Summary With Setup Insights - Newser
What makes Adverum Biotechnologies Inc. stock price move sharplyReal-Time Investment Picks with Accuracy - Newser
How to build a dashboard for Adverum Biotechnologies Inc. stockDeep Stock Performance and Volatility Analysis - Newser
Published on: 2025-08-11 03:29:27 - Newser
Is Adverum Biotechnologies Inc. stock bottoming outReal Trader Watchlist with Entry Targets - Newser
What to do if you’re stuck in Adverum Biotechnologies Inc.High Confidence Strategy with Trend Alignment - Newser
Adverum Biotechnologies Inc. stock prediction for this weekChart Driven Opportunity Scanner with Alerts - Newser
Is Adverum Biotechnologies Inc. a candidate for recovery playMarket Opportunity Tracker for Swing Traders - Newser
Adverum Biotechnologies Inc expected to post a loss of $2.25 a shareEarnings Preview - TradingView
Adverum Biotechnologies shares fall 2.38% intraday after executives to participate in H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
Adverum Leadership to Share Latest Ophthalmology Insights at H.C. Wainwright Conference - Stock Titan
What drives Adverum Biotechnologies Inc. stock priceStrong return on assets - Jammu Links News
What are analysts’ price targets for Adverum Biotechnologies Inc. in the next 12 monthsHigh-octane investment gains - Jammu Links News
How volatile is Adverum Biotechnologies Inc. stock compared to the marketGame-changing returns - Jammu Links News
Is Adverum Biotechnologies Inc. stock overvalued or undervaluedUnlock daily stock market insights for success - Jammu Links News
Should I hold or sell Adverum Biotechnologies Inc. stock in 2025Discover stock picks with superior returns - Jammu Links News
Is Adverum Biotechnologies Inc. a good long term investmentExplosive market performance - Jammu Links News
Pattern recognition hints at Adverum Biotechnologies Inc. upsideReal-Time Equity Price Action Analysis - newser.com
How does Adverum Biotechnologies Inc. generate profit in a changing economyHigh-yield market plays - Jammu Links News
Published on: 2025-08-03 12:31:10 - Jammu Links News
When is Adverum Biotechnologies Inc. stock expected to show significant growthHigh-octane financial growth - Jammu Links News
What are the latest earnings results for Adverum Biotechnologies Inc.Free Expert Stock Watchlist - Jammu Links News
What are Adverum Biotechnologies Inc. company’s key revenue driversBuild a diversified portfolio for risk management - Jammu Links News
What is the risk reward ratio of investing in Adverum Biotechnologies Inc. stockAchieve consistent profits with proven strategies - Jammu Links News
How many analysts rate Adverum Biotechnologies Inc. as a “Buy”Maximize returns with disciplined trading approaches - Jammu Links News
Why is Adverum Biotechnologies Inc. stock attracting strong analyst attentionRapidly expanding wealth - Jammu Links News
Adverum Biotechnologies Inc Azioni (ADVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adverum Biotechnologies Inc Azioni (ADVM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER |
May 15 '25 |
Sale |
2.00 |
924 |
1,848 |
13,768 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR |
May 15 '25 |
Sale |
2.00 |
9,126 |
18,252 |
87,488 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 27 '25 |
Buy |
5.19 |
16,593 |
86,089 |
141,800 |
| Leonard Braden Michael | 10% Owner |
Apr 22 '25 |
Buy |
3.00 |
300,000 |
900,000 |
3,057,526 |
| Leonard Braden Michael | 10% Owner |
Apr 23 '25 |
Buy |
2.98 |
50,000 |
148,950 |
191,800 |
| Leonard Braden Michael | 10% Owner |
Mar 31 '25 |
Buy |
4.38 |
19,566 |
85,668 |
2,742,317 |
| Leonard Braden Michael | 10% Owner |
Apr 02 '25 |
Buy |
4.04 |
15,209 |
61,408 |
2,757,526 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 18 '25 |
Buy |
4.69 |
62,341 |
292,418 |
2,667,161 |
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):